Metropolis Healthcare has posted strong earnings for the third quarter of the financial year 2025, recording a 15.4% year-on-year (YoY) increase in net profit. The diagnostics chain reported a profit of ₹31.4 crore, up from ₹27.2 crore in the same period last year. Revenue from operations also saw an 11% jump, reaching ₹322.8 crore compared to ₹291 crore in Q3 FY24.
Steady Growth in Earnings and Margins
The company’s EBITDA (earnings before interest, taxes, depreciation, and amortization) rose by 11.2% in the December quarter, hitting ₹72 crore, up from ₹64.8 crore in the previous fiscal. Despite rising costs in the healthcare sector, Metropolis maintained an EBITDA margin of 22.3%, which remained largely stable from last year’s levels.
One of the key factors driving this consistent performance is the company’s operational efficiency. Over time, Metropolis has been expanding its diagnostic capabilities while focusing on cost management and optimized processes, strengthening its foothold in the industry.
Stock Market Performance Reflects Investor Confidence
Metropolis Healthcare’s positive Q3 results have also boosted investor sentiment. On the National Stock Exchange (NSE), the stock is trading at ₹1869, marking a 3.49% gain from its previous close.
The stock has been on an upward trajectory, delivering a 7.17% gain over the last year. Analysts believe the company’s steady revenue growth, stable margins, and strategic expansion in diagnostics contribute to its positive outlook in the market.
Expansion and Operational Strength Continue to Drive Growth
Metropolis Healthcare has consistently worked towards broadening its diagnostic offerings while ensuring operational efficiency. The company’s ability to adapt to market demands and expand its reach in key regions has played a vital role in maintaining its profitability.
- Revenue growth of 11% signals sustained demand for diagnostic services.
- EBITDA margin stability at 22.3% shows controlled operational costs.
- Stock price gain of 7.17% over one year reflects market confidence in long-term performance.
The diagnostics industry remains highly competitive, but Metropolis Healthcare’s financial stability and expansion strategies keep it on track for further growth.
